Theramex Spain company information, Employees & Contact Information

UK marketing watchdog slams Theramex for 'wholly unacceptable' compliance failings Fierce Pharma

Daré Bioscience and Theramex Announce Co-Development and GlobeNewswire

Linzagolix▼ – A Flexible Treatment Option for Women with Uterine Fibroids European Medical Journal

NHS patients to access Theramex’s endometriosis pill following NICE recommendation PMLiVE

Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia ACCESS Newswire

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc. Business Wire

Theramex Ganirelix News-Medical

UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe Reuters

NICE supports Theramex’s Eladynos for post-menopause osteoporosis Pharmaceutical Technology

CVC Fund VI agrees exit of Theramex cvc.com

Latham Advises on CVC’s Sale of Theramex to PAI Partners and Carlyle Latham & Watkins LLP

Carlyle, PAI Agree to Buy CVC’s Women’s Health Business Theramex Bloomberg

International Women's Day sees Theramex reinforce its commitment to women's health International Women's Day

Theramex receives recommendation for YSELTY in Scotland Pharmafile

Theramex The Pharma Letter

Behind the deal: Carlyle and PAI on women’s healthcare Private Equity News

PE Today: CVC Exits Theramex, Estancia Invests in Financial Services Middle Market Growth

Theramex's uterine fibroid drug Yselty backed for NHS use pharmaphorum

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women* Business Wire

Carlyle, PAI Nearing $1.4 Billion Deal for CVC’s Theramex Bloomberg

Theramex enters into an exclusive licensing agreement with Radius Health Inc to commercialise ELADYNOS® Taylor Wessing

IQWiG Finds "Not Proven" Added Benefit for Theramex’s Yselty in Endometriosis, Citing Persistent Lack of Comparative Data Under AMNOG NAVLIN DAILY

With approval in sight, ObsEva sells regional rights to women's health drug for tiny upfront Fierce Biotech

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS ® ▼ in the European Economic Area, the United Kingdom, Australia and Brazil Via TT

Theramex gains European rights to Duphaston and Femoston from Viatris Pharmaceutical Technology

Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety The Independent

Theramex to market Prolia biosimilar in Europe and Australia Generics and Biosimilars Initiative

Carlyle and PAI Partners to acquire Theramex from CVC Funds The Pharma Letter

Working your way up in women’s health Pf Media

Theramex wins decentralized procedure approval in EU, UK for hormone drug Drug Delivery Business

Theramex And Alkem’s Enzene Ally On Denosumab Citeline News & Insights

NICE Draft Backs Yselty by Theramex for Uterine Fibroid Treatment NAVLIN DAILY

Theramex to buy ex-US rights of BIJUVA and IMVEXXY from TherapeuticsMD Pharmaceutical Business review -

Theramex launches osteoporosis drug Livogiva in Europe Pharmafile

Theramex joins levloan pipeline GlobalCapital

Theramex Launches Non-hormonal Femarelle® on the 12th of May NTB Kommunikasjon

Theramex Buys Janssen’s Evorel Amid Ongoing HRT Shortages Citeline News & Insights

Real world evidence demonstrates that risedronate GR (Actonel® GR) has superior outcomes for fracture risk reduction in patients with osteoporosis compared to immediate release oral bisphosphonates NTB Kommunikasjon

Theramex beats guidance with strong uptake from existing lenders GlobalCapital

Alert: Evorel Sequi Dispensing Doctors' Association

Private equity giants snap up women’s health firm Theramex for £1.2bn City AM

Theramex launches first body-identical combined hormone therapy treatment Pf Media

Bedell Cristin advises on sale of Theramex by CVC channeleye.media

Theramex Launches Antadys In France The Pharma Letter